These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15155547)

  • 21. Hydroperoxy-10,12-octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate.
    Kimzey AL; Weitz KK; Guengerich FP; Zangar RC
    Biochemistry; 2003 Nov; 42(43):12691-9. PubMed ID: 14580217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction.
    Fukuda K; Ohta T; Yamazoe Y
    Biol Pharm Bull; 1997 May; 20(5):560-4. PubMed ID: 9178939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
    Sagir A; Schmitt M; Dilger K; Häussinger D
    Digestion; 2003; 68(1):41-8. PubMed ID: 12949438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
    Filppula AM; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of umbelliferous or citrus crude drugs and their relative prescriptions.
    Guo LQ; Taniguchi M; Chen QY; Baba K; Yamazoe Y
    Jpn J Pharmacol; 2001 Apr; 85(4):399-408. PubMed ID: 11388644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral erythromycin and the risk of sudden death.
    Amory JK; Amory DW
    N Engl J Med; 2005 Jan; 352(3):301-4; author reply 301-4. PubMed ID: 15669119
    [No Abstract]   [Full Text] [Related]  

  • 29. Mechanism of cytochrome P450-3A inhibition by ketoconazole.
    Greenblatt DJ; Zhao Y; Venkatakrishnan K; Duan SX; Harmatz JS; Parent SJ; Court MH; von Moltke LL
    J Pharm Pharmacol; 2011 Feb; 63(2):214-21. PubMed ID: 21235585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice.
    Rashid J; McKinstry C; Renwick AG; Dirnhuber M; Waller DG; George CF
    Br J Clin Pharmacol; 1993 Nov; 36(5):460-3. PubMed ID: 12959295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
    Klees TM; Sheffels P; Dale O; Kharasch ED
    Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
    Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
    Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Properties and regional expression of a CYP3A-like protein in channel catfish intestine.
    James MO; Lou Z; Rowland-Faux L; Celander MC
    Aquat Toxicol; 2005 May; 72(4):361-71. PubMed ID: 15848255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
    Martin NE; Howell SR; Martin LL; Cirillo I; Barrett JS
    J Clin Pharmacol; 2004 Apr; 44(4):379-87. PubMed ID: 15051745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
    Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
    Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human liver cytochrome P450 by star fruit juice.
    Zhang JW; Liu Y; Cheng J; Li W; Ma H; Liu HT; Sun J; Wang LM; He YQ; Wang Y; Wang ZT; Yang L
    J Pharm Pharm Sci; 2007; 10(4):496-503. PubMed ID: 18261370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid.
    Wang YP; Yan J; Fu PP; Chou MW
    Toxicol Lett; 2005 Mar; 155(3):411-20. PubMed ID: 15649625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. White and colored grapefruit juice produce similar pharmacokinetic interactions.
    Uesawa Y; Abe M; Mohri K
    Pharmazie; 2008 Aug; 63(8):598-600. PubMed ID: 18771009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction.
    Li P; Callery PS; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jul; 35(7):1203-8. PubMed ID: 17452418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.